<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783545</url>
  </required_header>
  <id_info>
    <org_study_id>VLX-1005-001</org_study_id>
    <nct_id>NCT04783545</nct_id>
  </id_info>
  <brief_title>Phase I Study of VLX-1005 in Healthy Subjects</brief_title>
  <official_title>A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Intravenous VLX-1005 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veralox Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veralox Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal objective of this study is to describe the safety of and tolerability to single&#xD;
      and multiple doses of VLX-1005 in healthy subjects following intravenous (IV) administration.&#xD;
&#xD;
      Other exploratory objectives are:&#xD;
&#xD;
      To evaluate the pharmacokinetics and pharmacodynamics of VLX-1005 following IV&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events</measure>
    <time_frame>Baseline up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Meet the Markedly Abnormal Criteria for 12-lead Electrocardiogram (ECG) or Telemetry Parameters at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Meet the Markedly Abnormal Criteria for Laboratory Values at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(inf)</measure>
    <time_frame>day 1 pre-infusion and at multiple time points (up to 36 hours) post infusion</time_frame>
    <description>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for VLX-1005</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C(max)</measure>
    <time_frame>day 1 at the end of infusion (1 hour after infusion starts)</time_frame>
    <description>Plasma Concentration at the end of Infusion for VLX-1005</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>day 1 pre-infusion and at multiple time points (up to 36 hours) post infusion</time_frame>
    <description>Terminal Disposition Phase Half-life for VLX-1005</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of 12-Lipoxygenase Inhibition</measure>
    <time_frame>day 1 pre-infusion and at multiple time points (up to 36 hours) post infusion</time_frame>
    <description>12-HETE measurement in serum</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Safety and Tolerability in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose Cohorts 1-6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: VLX-1005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Cohorts 1-6, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose Cohorts 7-9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: VLX-1005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose Cohorts 7-9, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VLX-1005</intervention_name>
    <description>VLX-1005 infusion</description>
    <arm_group_label>Multiple Ascending Dose Cohorts 7-9</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohorts 1-6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo infusion</description>
    <arm_group_label>Multiple Ascending Dose Cohorts 7-9, Placebo</arm_group_label>
    <arm_group_label>Single Ascending Dose Cohorts 1-6, Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, adult, male or female (non-lactating and not of childbearing potential)&#xD;
             subjects age 19 to 55 inclusive.&#xD;
&#xD;
          2. Females must have undergone one of the following sterilization procedures at least 6&#xD;
             months prior to the first dosing:&#xD;
&#xD;
               1. hysteroscopic sterilization&#xD;
&#xD;
               2. bilateral tubal ligation or bilateral salpingectomy&#xD;
&#xD;
               3. hysterectomy&#xD;
&#xD;
               4. bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year&#xD;
                  prior to the first dosing and follicle stimulating hormone (FSH) serum levels&#xD;
                  consistent with postmenopausal status.&#xD;
&#xD;
          3. Good general health, with no significant medical history. Subjects must have no&#xD;
             clinically significant abnormalities on physical examination at screening, and/or&#xD;
             before administration of the initial dose of study drug.&#xD;
&#xD;
          4. Body weight â‰¥ 50 kg at the screening visit.&#xD;
&#xD;
          5. Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive.&#xD;
&#xD;
          6. Has laboratory values (clinical chemistry and hematology) within the normal reference&#xD;
             range. Deviations from this range may be acceptable if they are considered 'not&#xD;
             clinically significant' (NCS) by the PI.&#xD;
&#xD;
          7. Males who have not been vasectomized participating in the study must agree to use at&#xD;
             least 2 approved methods of contraception (ie double-barrier or barrier plus&#xD;
             hormonal), or abstain from sexual intercourse, from Day -2 to 4 weeks after dosing (or&#xD;
             last dose Parts B)&#xD;
&#xD;
          8. Is a non-smoker and must not have used any nicotine products within three months prior&#xD;
             to screening.&#xD;
&#xD;
          9. Able and willing to attend the necessary visits to the study center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Blood donation or recipient of blood transfusion in previous 12 weeks.&#xD;
&#xD;
          2. History of clinically significant endocrine, neurological, gastrointestinal,&#xD;
             cardiovascular, hematological, hepatic, immunological, renal, respiratory, or&#xD;
             genitourinary abnormalities or diseases. Cardiovascular history should include&#xD;
             assessment of risk factors for Torsades de Pointes Risk (e.g., heart failure,&#xD;
             pulmonary edema, cardiomyopathy, hypokalemia, hypomagnesemia, or hypocalcemia, or&#xD;
             family history of Long QT Syndrome, syncope or sudden death).&#xD;
&#xD;
          3. History of neoplastic disease (with the exception of adequately treated&#xD;
             non-melanomatous skin carcinoma).&#xD;
&#xD;
          4. Mentally or legally incapacitated (e.g., has significant emotional problems at the&#xD;
             time of Screening Visit or expected during the conduct of the study, or has a history&#xD;
             of a clinically significant psychiatric disorder within the last 5 years).&#xD;
&#xD;
          5. Fever (body temperature &gt;38C) or symptomatic viral/bacterial infection or use of&#xD;
             antibi-otics within 2 weeks prior to Screening.&#xD;
&#xD;
          6. Supine resting blood pressure (BP) &gt;140/90 mmHg or heart rate (HR) outside the range&#xD;
             40 to 100 beats per minute at Screening and at Day -1.&#xD;
&#xD;
          7. Clinically significant abnormality on ECG performed at the Screening Visit or prior to&#xD;
             administration of the initial dose of study drug. (Sick sinus syndrome, second or&#xD;
             third degree atrioventricular block, myocardial infarction, symptomatic or significant&#xD;
             cardiac arrhythmia, prolonged QTcF interval, or bundle branch block.&#xD;
&#xD;
          8. Out of range (on repeat) testing for coagulation tests including fibrinogen.&#xD;
&#xD;
          9. Clinically significant laboratory abnormalities including: Impaired renal function&#xD;
             (estimated creatinine clearance (CrCl) of &lt;80 mL/minute based on CrCl = (140-age&#xD;
             [years])(body weight [kg])/(72)(serum creatinine [mg/dL])).&#xD;
&#xD;
         10. Positive test for hepatitis C antibody, hepatitis B surface antigen, or human&#xD;
             immunodefi-ciency virus (HIV) antibody at Screening.&#xD;
&#xD;
         11. Participants with a positive toxicology screening panel (urine test including&#xD;
             qualitative identiÂ¬fication of barbiturates, tetrahydrocannabinol, amphetamines,&#xD;
             benzodiazepines, opiates, cocaine, cotinine and ethanol).&#xD;
&#xD;
         12. Participants with a history of substance abuse or dependency or history of&#xD;
             recreational IV drug use (by self-declaration).&#xD;
&#xD;
         13. Participant has a suspected history of alcohol abuse in the 6 months prior to&#xD;
             screening.&#xD;
&#xD;
         14. Use of NSAIDs, aspirin or aspirin-containing medications (and other medications&#xD;
             affecting platelet function [for example cilostazol, clopidogrel, ticagrelor,&#xD;
             prasugrel, dipyridamole]) in the 14 days prior to dosing with study medication.&#xD;
&#xD;
         15. Unable to refrain from or anticipates the use of any medications, including&#xD;
             prescription and non-prescription drugs and herbal remedies (such as St. John's Wort&#xD;
             [Hypericum perforatum]), beginning 14 days (or 5 half-lives, whichever is longer)&#xD;
             before administration of the initial dose of study drug and continuing throughout the&#xD;
             study until the final study visit. There may be certain medications that are permitted&#xD;
             at the discretion of the Investigator and Sponsor (including&#xD;
             paracetamol/acetaminophen, medications for the treatment of AEs following&#xD;
             administration of study drug).&#xD;
&#xD;
         16. Subjects who are unlikely to comply with the study protocol or, in the opinion of the&#xD;
             investigator, would not be a suitable candidate for participation in the study.&#xD;
&#xD;
         17. Have participated in any other investigational drug trial within 30 days of dosing in&#xD;
             the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Hunt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Maloney, PhD</last_name>
    <phone>3013603502</phone>
    <email>Dave@veralox.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion, Inc.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Badgett, MBA</last_name>
      <phone>402-476-2811</phone>
      <email>angie.badgett@celerion.com</email>
    </contact>
    <investigator>
      <last_name>Allen Hunt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

